MedPath

TK-642 Long-Term Administration Study

Phase 3
Conditions
ncontrollable cancer pain
Registration Number
JPRN-jRCT2080221269
Lead Sponsor
TEIKOKU SEIYAKU CO., LTD.
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Sex
All
Target Recruitment
Not specified
Inclusion Criteria

1)Patients who were successful in titration of TK-642 in TK-642 Phase 2 Study
2)Patients who can give informed consent

Exclusion Criteria

Not provided

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Safety
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath